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ABSTRACT
Objective. The aim of this study was to analyse the sur-
vival impact of primary tumor nodal status (N0/N?) in
patients with resectable colorectal liver metastases (CLM),
and to determine the value of circulating and disseminated
tumor cells (CTCs/DTCs) in this setting.
Methods. In this prospective study of patients undergoing
resection of CLM from 2008 to 2011, peripheral blood was
analyzed for CTCs using the CellSearch System, and
bone marrow was sampled for DTC analyses just prior to
hepatic resection. The presence of one or more tumor cells
was scored as CTC/DTC-positive. Following resection of
the primary tumor, the lymph nodes (LNs) were examined
by routine histopathological examination.
Results. A total of 140 patients were included in this
study; 38 patients (27.1%) were negative at the primary
colorectal LN examination (N0). CTCs were detected in
12.1% of all patients; 5.3% of patients in the N0 group and
14.7% of patients in the LN-positive (N?) group
(p = 0.156), with the LN-positive group (N?) consisting
of both N1 and N2 patients. There was a significant dif-
ference in recurrence-free survival (RFS) when analysing
the N0 group versus the N? group (p = 0.007) and CTC-
positive versus CTC-negative patients (p = 0.029). In
multivariate analysis, CTC positivity was also significantly
associated with impaired overall survival (OS) [p = 0.05],
whereas DTC positivity was not associated with survival.
Conclusion. In this cohort of resectable CLM patients,
27% had primary N0 colorectal cancer. Assessment of
CTC in addition to nodal status may contribute to improved
classification of patients into high- and low-risk groups,
which has the potential to guide and improve treatment
strategies.
In surgery for colorectal cancer (CRC), primary tumors
are resected with curative intent, if possible. However,
more than 25% of CRC patients with localized disease at
diagnosis will die as a result of cancer relapse,1,2 with liver
being the most frequent metastatic site.1–3
Postoperative staging of the primary cancer is based on
histological examination of the specimen, traditionally
according to the tumor, node, metastases (TNM) staging
system.4 Currently, the indication for adjuvant treatment is
founded on this staging as colon cancer patients with lymph
node (LN) involvement are offered chemotherapy postop-
eratively. Although the prognosis of patients with node-
positive disease is inferior to those with node-negative dis-
ease, the outcome differs highly within the same TNM
stage.5 In fact, between 25 and 40% of patients with primary
node-negative CRC will develop liver metastases.5–9
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Traditionally, the development of metastases has been
understood as a sequential cancer progression where
malignant transformation of the epithelial cells initially
takes place in the intestinal mucosa, then infiltrates into the
intestinal wall and therafter secondary LN involvement,
and, subsequently , metastasize to distant organs. Accord-
ingly, a high-risk patient for future relapse of a non-
metastatic cancer will then be a patient with LN involve-
ment.10,11 However, in agreement with recent
understanding of cancer biology, cancer cell dissemination
may occur at all stages of cancer development.12,13
The presence of circulating tumor cells (CTCs) is a sig-
nificant prognostic factor in both non-metastatic14 and
metastatic CRC.15–17 Disseminated tumor cells (DTCs) in the
bone marrow (BM) have a prognostic impact in CRC patients,
at least in long-term follow-up.18 The aim of the present study
was to determine the relationship between primary tumor
nodal status and CTC and DTC status in relation to survival in
patients resected for colorectal liver metastases (CLM).
METHODS
Patients
Patients included in this study represent a subgroup from a
prospective cohort study of 194 CLM patients referred to Oslo
University Hospital for surgical treatment from May 2008 to
December 2011. This cohort has been previously described in
detail by Seeberg et al.15 In order to obtain a homogenous study
population of CLM patients with resectable liver metastases
and reliable LN status for the present analysis, two patients
without resection of their primary tumor, and hence unknown
nodal status, were excluded. Thirteen of the 60 node-negative
patients had received neoadjuvant radiotherapy and/or
chemotherapy before resection of the primary tumor, and were
excluded because of uncertain nodal status. Another three
patients had an inadequate number of lymph nodes resected
(\8), according to the present Norwegian guidelines,19 and
were therefore excluded. In addition, 17 patients were evaluated
as primary unresectable for their liver metastases. In 19 patients,
the liver metastases were non-resectable peroperatively or due
to progression after the first-stage liver resection. After exclu-
sion of all these patients, 140 patients remained and were
eligible for the present analysis (Fig. 1). Clinical follow-up
consisted of regular consultations every 4 months, with clinical
and radiological assessments. Recurrence was determined as
radiologically-proven relapse of the disease.
Ethics/Study Approval
All patient characteristics were registered prospectively
in a database using the Filemaker Pro Advanced
documentation (Santa Clara, CA, USA). The study proto-
col was approved by the Regional Ethical Committee in
Oslo, Norway, and the Oslo University Hospital Patient-
Surveillance Service. The database was approved by the
Data Protection Officer for Research, and permission for
biobanking was obtained from the National Health
Department.
Circulating Tumor Cell (CTC) Detection
The US FDA-approved CellSearch System (Janssen
Diagnostics LLC, Raritan, NJ, USA) was used for CTC
detection. The samples were taken under general anesthe-
sia, just prior to liver resection from peripheral blood. The
method has been previously described in detail.20 Blood
samples were collected into CellSave tubes, one tube per
patient (7.5 ml), and the samples were kept at room tem-
perature and processed at the Micrometastasis Laboratory,
Oslo University Hospital, within 96 h of collection. CTC
positivity was defined as one or more CTCs detected per
sample of blood.21
Bone Marrow Preparation and Disseminated Tumor
Cell (DTC) Detection
The BM aspirations were performed at the same time as
the CTC sampling, by bilateral aspiration from the crista
iliaca anterior (5 ml BM from each site), and processed as
previously described.22 As the CellSearch System is not
recommended or validated for BM analyses, immunocy-
tochemical detection was performed manually by density
centrifugation using ficoll-hypaque to isolate the BM
mononuclear cells, followed by the preparation of cytos-
pins. The spins were immunostained using anticytokeratin
antibodies AE1/AE3, and screened using the Ariol SL-50
automated screening system to identify epithelial cancer
cells.22,50 The same number of slides were analyzed with
an irrelevant control antibody to rule out false positives.
All immunopositive candidate cells were evaluated by a
pathologist (EB), and only cells with immune morphology
satisfying the standard criteria for DTCs were scored as
positive. DTC positivity was defined as one or more DTCs
detected, and thus DTC detection is based on a different
system than CTC detection with separate sensitivity and
specificity.
Pathological Examination
The specimens were analyzed at the local hospital,
assessing tumor differentiation, resection margins, and T
status. No assessment of KRAS status or microsatellite
instability were performed. LNs exceeding 3 mm were
divided into two or more parts parallel to their long axis,
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and all nodes were examined by routine microscopy, i.e. in
3–4 lm hematoxylin and eosin-stained sections. Patients
were registered as being LN-positive (N?) or LN-negative
(N0); the N? group included both N1 (67 patients) and N2
(35 patients) [Table 1]. According to the Norwegian
guidelines at the time,23 immunohistochemistry or poly-
merase chain reaction (PCR) analyses were not routinely
performed.
Statistical Methods
Data were analyzed using IBM SPSS version 20 (IBM
Corporation, Armonk, NY, USA) and STATA 11.0 (Sta-
taCorp LP, College Station, TX, USA). Differences in
continuous variables were tested using an independent
sample t test and the Pearson Chi square test for contin-
gency tables. The Fisher’s exact test was used to compare
ratios. An explanatory strategy was used to investigate the
relationship between N status and survival. All other
variables were only of interest as possible confounders or
effect modifiers of this association. A Mantel–Haenszel
stratification analysis using the patient years (time) model
was performed to quantify confounders and to pinpoint
effect modifiers, using the Breslow–Day test of
heterogeneity.
Adjustment for multiple confounders was carried out
using the Cox proportional hazard regression model with a
manual backward elimination procedure. Kaplan–Meier
survival curves were used to determine differences in
survival between N0/N? , and outcomes were recorded as
recurrence-free survival (RFS) and overall survival (OS).
OS/RFS was defined as the number of days from resection
of CLM to death/radiological recurrence. The association
between N status and survival was quantified by hazard
ratio (HR) with its 95% confidence interval (CI). Statistical
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FIG. 1 Study selection process for the cohort of 194 CLM patients, selecting the actual study population of 140 patients with resectable CLM.
CLM colorectal liver metastases
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TABLE 1 Characteristics of the CLM patient cohort [n = 140]
N0 N? p-Value
[n = 38] (%) [n = 102] (%)
Age, years (±SD) 64.4 (11.0) 65.1 (9.2) 0.71a
Sex 0.81b
Males 21 (55.3) 54 (52.9)
Females 17 (44.7) 48 (47.0)
Primary 0.007b
Colon 32 (84.2) 61 (59.9)
Rectum 6 (15.8) 41 (40.1)
T status 0.001c
T2 11 (28.9) 3 (2.9)
T3 25 (65.8) 82 (80.4)
T4 1 (2.6) 15 (14.7)
Nodal statuse 38 (27.1) 102 (72.9)
CEA (range) 3.5 (1–106) 6 (1–1381) 0.06d
Liver metastases 0.002c
Synchronous 15 (39.5) 70 (68.7)
Metachronous 23 (60.5) 32 (31.3)
Neoadjuvantf 0.004c
Yes 15 (39.5) 66 (66.7)
No 23 (60.5) 33 (33.3)
Adjuvantg 0.14c
Yes 21 (55.3) 68 (68.7)
No 17 (44.7) 31 (31.3)
CTCs 0.16b
Positive, C1 CTC 2 (5.3) 15 (14.7)
Negative 36 (94.7) 87 (85.3)
DTCs 0.73b
Positive, C1 DTC 4 (10.5) 8 (7.8)
Negative 34 (89.5) 94 (92.2)
Death 0.27c
Yes 7 (18.4) 28 (27.5)
No 31 (81.6) 74 (72.5)
Recurrence 0.008c
Yes 19 (50.0) 75 (73.5)
No 19 (50.0) 27 (26.5)
CLM colorectal liver metastases, SD standard deviation, CEA carcinoembryonic antigen, CTCs circulating tumor cells, DTCs disseminated tumor
cells
a Independent sample t-test
b Fisher’s exact test
c Pearson’s Chi square test
d Mann–Whitney U test. The following variables have missing values: T status, n = 3; neoadjuvant treatment, n = 3; adjuvant treatment,
n = 3
e In the lymph node-positive group (N?), 67 were N1 and 35 were N2. Median number of lymph nodes in the N0 group was 14 (8–53)
f Neoadjuvant treatment before liver resection (FOLFOX, n = 69; FOLFIRI, n = 3; FOLFIRI-bevacizumab, n = 7; folinic acid-fluorouracil,
n = 2)
g Adjuvant treatment after liver resection (FOLFOX, n = 74; FOLFIRI, n = 1; FOLFIRI-bevacizumab, n = 12; folinic acid-fluorouracil,
n = 2)
L. T. Seeberg et al.
RESULTS
Patients
Table 1 summarizes the characteristics of the 140 CLM
patients, with 27.1% N0 (n = 38) and 72.9%
N? (n = 102) tumors. A T2 primary tumor was signifi-
cantly more common in the N0 group (29.0% vs. 2.9% in
the N? group, p = 0.001) and primary colon cancer had a
higher frequency of N0 status than primary rectal cancer
(p = 0.007). Patients with RFS of more than 6 months
between the primary tumor resection and liver metastases
were more prone to have N0 primary cancer (60.5%), and,
correspondingly, patients with\6 months RFS were more
prone to have N? disease (68.7%, p = 0.002). Fifteen
patients in the N0 group (15/38) and 66 patients in the
N? group (66/102) received neoadjuvant treatment before
liver resection. Patients were followed until the date of
death or end of/last follow-up. The median follow-up time
was 24 (1–61) months.
CTC and DTC Detection
CTCs were detected in 12.1% of all patients; 5.3% in the
N0 group and 14.7% in the N? group (p = 0.156). Of the
17 CTC-positive patients, the number of CTCs detected
were one in four (four patients), two CTCs (four patients),
three CTCs (three patients), four CTCs (four patients) and
five CTCs (two patients).
Interestingly, 80.2% (69/86) of the CTC-negative
patients received neoadjuvant chemotherapy to the primary
tumor compared with 60% (9/15) in the CTC-positive
patients, supporting the sterilization effect of chemother-
apy. However, in CTC-negative patients, 62.4% (53/85)
received neoadjuvant treatment before liver resection
compared with 92.9% (13/14) of the CTC-positive patients.
To date, in this study a sterilization effect of chemotherapy
on CTCs cannot be confirmed (data not shown).
DTCs were present in 8.6% of all patients; 10.5% in the
N0 group and 7.8% in the N? group (p = 0.734). DTC
presence had no impact on either RFS or OS.
Recurrence-Free Survival
Kaplan–Meier curves show a significant difference in
RFS comparing N0 patients with N? patients (26 vs.
9 months, p = 0.007) [Fig. 2a]. There was also a signifi-
cant difference in RFS between CTC-positive and CTC-
negative patients (6 vs. 13 months, p = 0.029) [Fig. 2b].
The crude HR for N status of the primary tumor and
RFS after resection of the CLM was 1.95 (95% CI
1.17–3.23, p = 0.010). Potential confounders of the asso-
ciation between N status and RFS were identified, and the
results of the stratified analysis are shown in electronic
supplementary Table 1.
In the stratified analysis, the timing and number of liver
metastases, in addition to neoadjuvant chemotherapy, were
identified as possible confounders (confounding
effect[8%). By multivariate Cox regression analysis, the
number and timing of liver metastasis were identified as the
strongest confounders (Table 2).
Controlling for multiple confounding, the association
between N status and RFS remained statistically significant
(adjusted HR [HRadj] 1.74, 95% CI 1.07–2.83, p = 0.03).
Overall, an association was noted between N?/N0 and
synchronous/metachronous liver metastases and RFS
(p = 0.006; electronic supplementary Fig. 1).
Overall Survival
Kaplan–Meier analyses showed no significant difference in
OS between N0 and N? patients (Fig. 2c). Analysing CTC
status, no significant difference in OS between positive and
negative patients was detected (53 vs. 52 months, p = 0.098)
[Fig. 2d]. However, studying survival and CTC status in
N? patients, CTC-positive N? patients had impaired sur-
vival compared with CTC-negative N? patients (median
survival 27 vs. 52 months, p = 0.024) [Fig. 3].
The crude HR for the association between N status and
OS was 1.59 (95% CI 0.69–3.64, p = 0.274). Potential
confounders were identified, and the results of the stratifi-
cation analyses are shown in electronic supplementary
Table 2.
In multivariate Cox regression analysis, CTC positivity
and number of liver metastases were identified as the
strongest confounders (Table 3). When controlling for
multiple confounding, the association between N status and
OS was not statistically significant (HRadj 1.43, 95% CI
0.62–3.32, p = 0.065).
Mortality in CTC-positive patients was 2.3-fold higher
than in CTC-negative patients when adjusting for primary
nodal status and number of liver metastases (Table 3).
DISCUSSION
In this study of resectable CLM patients, 27% of
patients were N0 when examining their primary surgical
specimen LNs. The frequency of CTC positivity at the time
of CLM surgery was 12.1%, and was considerably higher
in the N? group compared with N0 patients. LN? CTC-
positive was associated with significant inferior RFS and
OS. In the N0 group, only 5.3% of patients were CTC-
positive; however, nodal status at primary surgery was not
significantly associated with a difference in OS (Fig. 2).
The presence of one or more CTCs at the time of CLM
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surgery was one of the strongest covariates for RFS and
OS. This is in agreement with previous reports, suggesting
CTCs are equal to, or even superior to, the conventional
staging tools in estimating prognosis.15, 24 The combination
of CTC and nodal status was superior to either variable
individually.25
The presence of LN metastases is a well-recognized
prognostic factor26–28 but the optimal number of LNs
required for adequate staging is uncertain. Evaluation of at
least 12 nodes is widely cited in clinical guidelines.29–31
LN harvest is affected by several factors, such as
microsatellite instability and tumor location.32 Rhabari
et al. showed that molecular detection of tumor cells in
regional LNs was associated with an increased risk of
disease recurrence and poor survival in patients with
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FIG. 2 (a) Recurrence-free survival according to lymph node status
(N?/N0) in 140 patients with resectable CLM (p\ 0.01). (b) Recur-
rence-free survival according to CTC status in peripheral blood
detected at liver surgery in 140 patients with resectable CLM
(p = 0.029). (c) Overall survival analysing lymph node status (N?/
N0) in 140 patients with resectable CLM (p = 0.267). (d) Overall
survival according to CTC status in the peripheral blood at liver
surgery in 140 patients with resectable CLM (p = 0.098). CLM
colorectal liver metastases, CTC circulating tumor cells
TABLE 2 Association between N?/N0 and recurrence-free survival after adjusting for multi-confounders in a cohort of 140 patients with CLM
(multivariate analysis)
Level HR 95% CI Standard error p-Value
N status N?/N0 1.78 1.02–3.13 0.43 0.04
No. of liver metastases [3/1–3 1.92 1.17–3.16 0.32 0.009
Synchronous liver metastasis Yes/no 1.45 0.91–2.31 1.08 0.12
CLM colorectal liver metastases, HR hazard ratio, CI confidence interval
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importance of adequate molecular examination of the
retrieved nodes for correct staging.33
In spite of general improvement in diagnostics, prog-
nostic tools, and surgical and pathological evaluation,
25–50% of CRC patients experience recurrence. On the
other hand, 50% of node-positive CRC patients seem to be
cured by surgery alone. Adjuvant treatment has been pro-
ven to increase survival in non-metastatic CRC,34,35 but the
survival benefit of chemotherapy treatment varies.36
Selection criteria for chemotherapy and targeted treatment
are warranted, and biological markers may contribute to
this.37
CTCs are components of the metastatic cascade, and
CTC presence has proven to be a strong predictor of sur-
vival in patients with early and metastatic epithelial cancer,
including CRC.38–41 The impact of CTCs on survival in
CRC has been reported in a meta-analysis by Rahbari et al.
but the study has been criticized for methodological
heterogeneity.40 A recent meta-analysis by Huang et al.
confirms the prognostic significance of CTCs detected
using the CellSearch system in CRC.24 Huang et al. con-
clude that uncertainties still remain regarding the optimal
sampling time for CTC analyses to provide the most
accurate prognostic information. Serial sampling seems to
represent an important tool for monitoring treatment.42,43
The cut-off value for CTC positivity differs between
studies. The impact of the number of CTCs on survival has
been published by our group.17 The low cut-off value in
this study (one or more CTCs per 7.5 ml of blood) was
chosen because the study included patients being treated
with chemotherapy, knowing the negative impact of such
treatment on CTC levels,44 as also reported in the present
study. Thus, the cut-off value of being CTC-positive in
metastatic CRC patients is not yet settled.45
In this study, 15 of the N0 patients had synchronous
liver metastases and all received neoadjuvant chemother-
apy. These patients had a significantly better RFS than
N? patients with synchronous liver metastases (electronic
supplementary Fig. 1). The high frequency of metastases in
the N0 patients supports the view that cancer cell con-
tamination occurs at different stages in cancer
development. In N0 patients with synchronous liver
metastases, the tumor cells have bypassed the LNs, and one
could hypothesize that the disease may be more chemore-
sponsive when limited to the liver.46,47 These patients may
be prime candidates for neoadjuvant treatment.
Supported by the results in our study, a possible approach
to improve prognostic accuracy could be to combine CTC
detection and N staging, as also suggested by Allen-Mersh
et al.25 and Van Dalum et al.48 This might improve selection
to adjuvant chemotherapy in both LN-negative and LN-
positive CRC patients. Serial CTC monitoring during fol-
low-up may further improve surveillance of metastatic CRC
patients.48 Our recent results indicate the potential impact of
detection of CTCs for prognosis and recurrence through
serial monitoring.47 In addition, further molecular charac-
terization of CTCs to identify therapeutic targets opens the
possibility of tailoring CRC treatment individually.
The presence of DTCs at primary surgery is reported to be
a prognostic biomarker of impaired survival in patients with
CRC in long-term follow-up.18 This may be explained by
DTCs representing dormant tumor cells with the ability to
later escape dormancy, proliferate, and cause relapse in
apparently curatively resected cancer patients, suggesting a
role for DTCs as a biomarker in CRC.49 In the present study,
the presence of DTCs in CLM surgery did not seem to have
an impact on survival, but the follow-up time was limited.
This study has several limitations. The short median
follow-up is partly because 40.8% of the study population
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FIG. 3 Overall survival analyzing the combination of lymph node
status (N?/N0) and CTC status at liver surgery in 140 patients with
resectable CLM. CTC circulating tumor cells, CLM colorectal liver
metastases
TABLE 3 Association between N?/N0 and overall survival after adjusting for multi-confounders in a cohort of 140 patients with CLM
(multivariate analysis)
Level HR 95% CI Standard error p-Value
N status N?/N0 1.43 0.61–3.32 0.55 0.40
No. of liver metastasis [3/1–3 2.07 1.00–4.28 0.54 0.05
CTC-positive Yes/No 2.31 1.00–4.28 0.66 0.05
CLM colorectal liver metastases, HR hazard ratio, CI confidence interval, CTC circulating tumor cell
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had died within 4 years of follow-up. More extensive fol-
low-up would further elucidate the clinical outcome for
these patients. Sampling of CTC and DTC was performed
at the time of liver surgery. Thus, we cannot exclude the
possibility that any chemotherapy given before sampling
(adjuvant for the primary or neoadjuvant for the liver
metastases) may have affected the CTC and DTC status.
This could explain a relative low rate of positivity. Only a
small number of N0 patients (n = 38) were analyzed, and
the frequency of CTC positivity among these patients was
low (5.3%). N0 CTC-positive patients appear to be a high-
risk group but further studies are needed to confirm this.
Due to non-standardized pathology reports at the time of
this study, more than 30% did not report vascular invasion.
Unfortunately, the presence of vascular invasion could not be
analyzed in the present study. Molecular analyses for char-
acterization of CTCs as microsatellite instability and KRAS/
BRAF mutation may also provide clinically relevant infor-
mation for prognosis and treatment options in these patients,
and should be further tested in clinical studies.
CONCLUSION
This study shows the presence of CTCs is associated
with impaired survival. CTC status seems to provide
additive prognostic information to LN status in patients
with CLM.
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